Marco Meglio

Overall, the data empower the potential of CAR-T cell therapy for patients with advanced multiple sclerosis that are refractory to conventional antibody-mediated B cell depletion.

Advancements in the detection and care of multiple sclerosis have led to improved diagnosis rates and a more multidisciplinary approach to treating the autoimmune disorder.

The company also submitted a request for a fast track designation specific to a subcutaneous version of lecanemab and is expected to hear back within 60 days from March 2024.

Overall, the reduction of hyperactivity of delta- and gamma-band activities in mTBI suggest the treatment may reduce deafferentation and GABA-ergic inhibitory interneuron dysfunctions.

The APPRAISE randomized clinical trial provided clinically meaningful evidence that early initiation of migraine prevention with erenumab was superior over other nonspecific oral migraine preventive medications.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis and MS mimics.

The randomized, double-blind, placebo-controlled trial failed to show any beneficial symptomatic effect of 4-month treatment with 1.75–3.5 mg/day bumetanide on Parkinson disease.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sharon Hesterlee, PhD. [LISTEN TIME: 10 minutes]

The findings were consistent with the chemical's known carcinogenicity and supportive of the emerging preclinical and epidemiological evidence that ties TCE exposure to patients with PD.

In a small-scale study, treatment with PRAX-628 resulted in significant reduction in the number of generalized photo paroxysmal response events.

Over the 24-week treatment period, satralizumab demonstrated a well tolerated safety profile that was consistent with its previous indication.

Following development and implementation of a simulation laboratory training session to all staff in the EMU, there were statistically significant improvements in orientation assessment, speech assessment, motor assessment, oxygen administration, and vital sign collection in the short-term reassessment.

With data showing significant therapeutic benefit on seizure reduction and other outcomes of cognition and behavior, Stoke will move forward with a new study to assess high doses of 70 mg STK-001 followed by continued dosing at 45 mg.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders and multiple system atrophy.

The CLARiTI study spans across all 37 Alzheimer Disease Research Centers, collecting evidence on imaging and blood-based biomarkers to generate etiologic patient profiles of mixed dementia.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 32 minutes]

TOPAMAD will include 70 children with epileptic spasms who experienced hormonal therapy failure to determine whether modified Atkins diet or topiramate is a more effective treatment approach.

Over a 6-week period, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared with those on placebo, with effects seen as early as week 2.

The phase 2 study for risvodetinib in Parkinson disease aims to halt disease progression and reverse functional loss.

The chief executive officer at Elixirgen Therapeutics provided commentary on the promise of the Bobcat mRNA, and the mechanism of action for mRNA-like therapies to treat Duchenne muscular dystrophy.

Despite the overall cohort not reaching statistical significance on the primary end point, a subgroup of patients on SLS-005 without AMX0035 performed better.

With the added coverage, it paves the way for individuals facing the hurdles of migraine disease to obtain an easy-to-use nonpharmacological option for both acute and preventive migraine care.

A panel of experts MS specialists provided commentary on the clinical development of these therapies, some of the specific agents within the pipeline, and how to navigate potential safety concerns.

A 24-hour subcutaneous infusion of ND0612 was superior to oral immediate-release levodopa–carbidopa at increasing on time without troublesome dyskinesia and reducing off time in adults with Parkinson disease.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

Shae Datta, MD, a neurologist and headache specialist at NYU Langone Health, discussed the effects of traumatic brain injury and the need to accurately diagnose patients in a timely manner.

Over an 18-month period, patients demonstrated significant increases in ON time with bemdaneprocel, even after stopping immunosuppressives 1 year into treatment.

The phase 2 multisite trial is expected. to include 498 patients to assess the efficacy, safety, and tolerability of Lu AG09222 as a potential migraine preventive.

Tim Siegert, PhD, chief operating officer and co-founder of Allyx Therapeutics, provided commentary on the recently announced positive phase 1b results for ALX-001, an agent in development for Alzheimer and Parkinson disease.

Over 61.1 patient-years of treatment experience, AOC 1001 was well tolerated in patients with DM1, with nausea and headache the most commonly reported adverse events.